Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 13/20 | 0.63 |
| ▸ | HTR3A | P46098 | 11/20 | 0.63 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400982 | 0.89 | HTR4 (0.79) | HTR4HTR3APARP1PARP2 | |
| SCHEMBL828864 | 0.89 | HTR4 (0.79) | HTR4HTR3APARP1PARP2 | |
| SCHEMBL1728189 | 0.87 | HTR4 (0.59) | HTR4HTR3APARP1PARP2 | |
| SCHEMBL1726614 | 0.85 | HTR4 (0.59) | HTR4HTR3ACHRM2 | |
| SCHEMBL1727585 | 0.85 | HTR4 (0.59) | HTR4HTR3APARP1ALDH1A1HPGD | |
| SCHEMBL1728064 | 0.83 | HTR4 (0.59) | HTR4HTR3A | |
| SCHEMBL1726873 | 0.79 | HTR4 (0.48) | HTR4HTR3APARP1PARP2CYP2C9 | |
| Felcisetrag SCHEMBL390795 | 0.77 | HTR4 (1.00) | HTR4HTR3A | |
| SCHEMBL828734 | 0.77 | HTR4 (0.84) | HTR4HTR3APARP1PARP2 | |
| SCHEMBL1728620 | 0.77 | HTR4 (0.49) | HTR4HTR3APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | claimed |